Previous Close | 2.1900 |
Open | 2.2000 |
Bid | 2.2000 x 2900 |
Ask | 2.3900 x 2200 |
Day's Range | 2.1900 - 2.3600 |
52 Week Range | 2.0700 - 34.0000 |
Volume | |
Avg. Volume | 554,285 |
Market Cap | 131.012M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.8500 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for GRPH
SOUTH SAN FRANCISCO, Calif., May 16, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today presented preclinical data for GPH102, the company’s differentiated gene replacement program for beta-thalassemia, in an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting. The hyb
SOUTH SAN FRANCISCO, Calif., May 12, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today reported recent business progress and first quarter 2022 financial results.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...